Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Market Formation Isn't Going According To Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.

Advertisement

Related Content

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Biosimilar User Fee Negotiations Won't Start Until 2016
As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register